CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
senofilcon A +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03222037
NCT03222037Phase 4Completed

Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers

Johnson & Johnson Vision Care, Inc.·interventional·Posted Jul 19, 2017·Updated Sep 10, 2019

In Brief

A Phase 4 clinical trial evaluating senofilcon A and Control for Visual Acuity. Completed, enrolled 49 participants across 1 site.

Detailed Summary

This is a bilateral, non-dispensing, randomized, cross-over, single-masked study. There are a total of 3 visits where all study endpoints will be measured in all subjects at baseline with habitual lenses and under the two testing treatments sequentially in separate visits based on the randomization scheme

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVisual Acuity
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJul 19, 2017
Enrollment StartJun 27, 2017
Primary CompletionAug 4, 2017
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9.0 years ago

Interventions

senofilcon Adevice

Acuvue Oasys 1-Day

Controldevice

Trial Frame with best spherocylindrical refraction (SCR)